Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu

Molecular Cancer Therapeutics

Volumn 12, Issue 6, 2013, Pages 979-991

  Cao, Yu ^a,b   Mohamedali, Khalid A ^a   Marks, John W ^a   Cheung, Lawrence H ^a   Hittelman, Walter N ^a   Rosenblum, Michael G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANZYME B; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; SERINE PROTEINASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRASTUZUMAB;

ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL SURVIVAL; FEMALE; GRANZYMES; HUMANS; MICE; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SERINE PROTEASES; SIGNAL TRANSDUCTION; SINGLE-CHAIN ANTIBODIES;

EID: 84879289517     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0002     Document Type: Article

References (50)

1. De LC, D'Alessio G. From immunotoxins to immunoRNases. Curr Pharm Biotechnol 2008;9:210-4.
2. Frankel AE. Reducing the immune response to immunotoxin. Clin Cancer Res 2004;10:13-5.
3. Smallshaw JE, Ghetie V, Rizo J, Fulmer JR, Trahan LL, Ghetie MA, et al. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat Biotechnol 2003;21:387-91.
4. Posey JA, Khazaeli MB, Bookman MA, Nowrouzi A, Grizzle WE, Thornton J, et al. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002;8:3092-9.
5. Hall PD, Virella G, Willoughby T, Atchley DH, Kreitman RJ, Frankel AE. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macro-phage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia. Clin Immunol 2001;100:191-7.
6. Hertler AA, Spitler LE, Frankel AE. Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma. Cancer Drug Deliv 1987;4:245-53.
7. Oh S, Todhunter DA, Panoskaltsis-Mortari A, Buchsbaum DJ, Toma S, Vallera DA. A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model. Pancreas 2012;41:789-96.
8. Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A 2008;105: 11311-6.
9. Mathew M, Verma RS. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci 2009;100: 1359-65.
10. Kurschus FC, Jenne DE. Delivery and therapeutic potential of human granzyme B. Immunol Rev 2010;235:159-71.
11. De LC, D'Alessio G. Human anti-ErbB2 immunoagents - immunoR-Nases and compact antibodies. FEBS J 2009;276:1527-35.
12. Lobe CG, Havele C, Bleackley RC. Cloning of two genes that are specifically expressed in activated cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1986;83:1448-52.
13. Trapani JA, Klein JL, White PC, Dupont B. Molecular cloning of an inducible serine esterase gene from human cytotoxic lymphocytes. Proc Natl Acad Sci U S A 1988;85:6924-8.
14. Kanatani I, Lin X, Yuan X, Manorek G, Shang X, Cheung LH, et al. Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin. Cancer Chemother Pharmacol 2011;68:979-90.
15. Rosenblum MG, Barth S. Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions. Curr Pharm Des 2009;15:2676-92.
16. Liu Y, Zhang W, Niu T, Cheung LH, Munshi A, Meyn RE Jr, et al. Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity. Neoplasia 2006;8:125-35.
17. Liu Y, Cheung LH, Thorpe P, Rosenblum MG. Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: directed apoptotic events in vascular endothelial cells. Mol Cancer Ther 2003;2: 949-59.
18. Liu Y, Cheung LH, Hittelman WN, Rosenblum MG. Targeted delivery of human pro-apoptotic enzymes to tumor cells: in vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol Cancer Ther 2003;2:1341-50.
19. Weidle UH, Georges G, Brinkmann U. Fully human targeted cytotoxic fusion proteins: new anticancer agents on the horizon. Cancer Genomics Proteomics 2012;9:119-33.
20. Stahnke B, Thepen T, Stocker M, Rosinke R, Jost E, Fischer R, et al. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther 2008;7:2924-32.
21. Dalken B, Giesubel U, Knauer SK, Wels WS. Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition. Cell Death Differ 2006;13:576-85.
22. Wang T, Zhao J, Ren JL, Zhang L, Wen WH, Zhang R, et al. Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells. Cancer Res 2007;67:11830-9.
23. Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res 2009;69:8987-95.
24. Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, et al. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther 2012;11:143-53.
25. Turk MJ, Reddy JA, Chmielewski JA, Low PS. Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. Biochim Biophys Acta 2002; 1559:56-68.
26. Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, et al. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer 2010;9:42.
27. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-9.
28. Plank C, Oberhauser B, Mechtler K, Koch C., Wagner E. Theinfluence of endosome-disruptive peptides on gene transfer using synthetic viruslike gene transfer systems. J Biol Chem 1994;269:12918-24.
29. Bongartz JP, Aubertin AM, Milhaud PG, Lebleu B. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res 1994;22:4681-8.
30. Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers-role of estrogen receptor and HER2 reactivation. Breast Cancer Res 2011;13:R121.
31. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009;69:6871-8.
32. Casi G, Neri D. Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release 2012;161:422-8.
33. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14:529-37.
34. King HD, Dubowchik GM, Mastalerz H, Willner D, Hofstead SJ, Firestone RA, et al. Monoclonal antibody conjugates of doxorubi-cin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. J Med Chem 2002;45: 4336-43.
35. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010;146:264-75.
36. Nagata S, Pastan I. Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv Drug Deliv Rev 2009;61:977-85.
37. Madhumathi J, Verma RS. Therapeutic targets and recent advances in protein immunotoxins. Curr Opin Microbiol 2012;15:300-9.
38. Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, et al. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci U S A 2012;109:11782-7.
39. Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, et al. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci U S A 2011;108:5742-7.
40. Trapani JA, Sutton VR. Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr Opin Immunol 2003;15:533-43.
41. Chowdhury D, Lieberman J. Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol 2008;26: 389-420.
42. Motyka B, Korbutt G, Pinkoski MJ, Heibein JA, Caputo A, Hobman M, et al. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 2000;103:491-500.
43. Kurschus FC, Bruno R, Fellows E, Falk CS, Jenne DE. Membrane receptors are not required to deliver granzyme B during killer cell attack. Blood 2005;105:2049-58.
44. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68: 9280-90.
45. Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther 2011;11:793-800.
46. Bedard PL, de AE, Cardoso F. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Curr Cancer Drug Targets 2009;9:148-62.
47. Hilgeroth A, Hemmer M, Coburger C. The impact of the induction of multidrug resistance transporters in therapies by used drugs: recent studies. Mini Rev Med Chem 2012;12:1127-34.
48. Hurvitz SA, Kakkar R. The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies. Ther Adv Med Oncol 2012;4:235-45.
49. Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs 2012;23: 765-76.
50. Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010;70:2528-37.